Mitake Information Corporation (TPEX:8284)
Taiwan · Delayed Price · Currency is TWD 63.80
+0.90 (1.43%)
Aug 12, 2025, 1:10 PM CST
Ligand Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 2,845 | 2,788 | 2,646 | 2,478 | 2,206 | 1,887 | Upgrade | |
Revenue Growth (YoY) | 3.08% | 5.37% | 6.80% | 12.33% | 16.88% | 12.84% | Upgrade |
Cost of Revenue | 2,195 | 2,131 | 2,075 | 1,887 | 1,696 | 1,414 | Upgrade |
Gross Profit | 649.09 | 657.1 | 570.89 | 590.83 | 510.24 | 473.67 | Upgrade |
Selling, General & Admin | 180.96 | 179.59 | 172.09 | 152.76 | 138.6 | 149.67 | Upgrade |
Research & Development | 198.46 | 187.82 | 166.27 | 159.03 | 141.41 | 161.2 | Upgrade |
Operating Expenses | 379.37 | 367.63 | 338.7 | 311.94 | 280.29 | 310.77 | Upgrade |
Operating Income | 269.72 | 289.48 | 232.19 | 278.89 | 229.95 | 162.9 | Upgrade |
Interest Expense | -0.22 | -0.29 | -0.24 | -0.05 | -0.08 | -0.11 | Upgrade |
Interest & Investment Income | 23.41 | 16.23 | 14.26 | 3.68 | 1 | 3.58 | Upgrade |
Currency Exchange Gain (Loss) | 19.38 | 19.38 | -0.07 | 28.64 | -4.09 | -17.55 | Upgrade |
Other Non Operating Income (Expenses) | -64.09 | 0.34 | -0.92 | 1.69 | 2.76 | 3.45 | Upgrade |
EBT Excluding Unusual Items | 248.21 | 325.13 | 245.22 | 312.85 | 229.54 | 152.26 | Upgrade |
Gain (Loss) on Sale of Investments | -2.79 | -2.79 | -4.45 | 35.35 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.06 | Upgrade |
Pretax Income | 245.42 | 322.35 | 240.77 | 348.2 | 229.54 | 152.2 | Upgrade |
Income Tax Expense | 54.49 | 64.9 | 45.56 | 61.55 | 41.24 | 30.28 | Upgrade |
Net Income | 190.93 | 257.45 | 195.21 | 286.65 | 188.3 | 121.93 | Upgrade |
Net Income to Common | 190.93 | 257.45 | 195.21 | 286.65 | 188.3 | 121.93 | Upgrade |
Net Income Growth | -16.08% | 31.88% | -31.90% | 52.23% | 54.44% | -33.44% | Upgrade |
Shares Outstanding (Basic) | 46 | 46 | 46 | 46 | 46 | 44 | Upgrade |
Shares Outstanding (Diluted) | 46 | 47 | 47 | 47 | 47 | 45 | Upgrade |
Shares Change (YoY) | -0.27% | 0.04% | -0.15% | 0.10% | 4.39% | 6.75% | Upgrade |
EPS (Basic) | 4.13 | 5.56 | 4.21 | 6.19 | 4.06 | 2.75 | Upgrade |
EPS (Diluted) | 4.11 | 5.53 | 4.20 | 6.15 | 4.05 | 2.74 | Upgrade |
EPS Growth | -15.87% | 31.67% | -31.71% | 51.85% | 47.81% | -37.59% | Upgrade |
Free Cash Flow | 113.47 | 209.6 | 268.37 | 395.68 | 126.42 | 8.3 | Upgrade |
Free Cash Flow Per Share | 2.45 | 4.51 | 5.77 | 8.50 | 2.72 | 0.19 | Upgrade |
Dividend Per Share | - | 4.000 | 3.500 | 4.000 | 3.001 | 2.357 | Upgrade |
Dividend Growth | - | 14.29% | -12.50% | 33.28% | 27.32% | -21.43% | Upgrade |
Gross Margin | 22.82% | 23.57% | 21.57% | 23.85% | 23.13% | 25.10% | Upgrade |
Operating Margin | 9.48% | 10.38% | 8.77% | 11.26% | 10.42% | 8.63% | Upgrade |
Profit Margin | 6.71% | 9.23% | 7.38% | 11.57% | 8.54% | 6.46% | Upgrade |
Free Cash Flow Margin | 3.99% | 7.52% | 10.14% | 15.97% | 5.73% | 0.44% | Upgrade |
EBITDA | 294.83 | 316.81 | 259.29 | 301.27 | 250.75 | 178.75 | Upgrade |
EBITDA Margin | 10.37% | 11.36% | 9.80% | 12.16% | 11.37% | 9.47% | Upgrade |
D&A For EBITDA | 25.1 | 27.33 | 27.1 | 22.38 | 20.8 | 15.86 | Upgrade |
EBIT | 269.72 | 289.48 | 232.19 | 278.89 | 229.95 | 162.9 | Upgrade |
EBIT Margin | 9.48% | 10.38% | 8.77% | 11.26% | 10.42% | 8.63% | Upgrade |
Effective Tax Rate | 22.20% | 20.13% | 18.92% | 17.68% | 17.97% | 19.89% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.